[Skip to Navigation]
April 1993

Effect of Oxymetazoline on Aqueous Humor Dynamics and Ocular Blood Flow in Monkeys and Rabbits

Author Affiliations

From the Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY (Drs Wang, Lee, Taniguchi, Podos, Serle, and Mittag), and the Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Mo (Dr Becker). Dr Podos is a consultant to Allergan Inc, Irvine, Calif, and Drs Podos and Mittag are consultants to Alcon Laboratories Inc, Fort Worth, Tex. The authors have no financial or proprietary interest in the drug oxymetazoline hydrochloride.

Arch Ophthalmol. 1993;111(4):535-538. doi:10.1001/archopht.1993.01090040127046

• Objective.  —To evaluate the ocular effects of oxymetazoline hydrochloride, an α2 agonist, in cynomolgus monkeys and albino rabbits.

Methods.  —Intraocular pressure was measured before and for 6 hours after application to glaucomatous monkey eyes. Outflow facility and aqueous flow rates were measured in normal monkey eyes. Uveoscleral outflow was measured in rabbit eyes. Ocular peak pulse volume was determined with the ocular blood flow system in normal and glaucomatous monkey eyes.

Results.  —Single applications of ozymetazoline reduced (P<.001) intraocular pressure up to 6.0±1.0 mm Hg (mean±SEM). Enhancement of the ocular hypotensive effect was observed with 5-day twicedaily administration. Outflow facility was unaltered; aqueous flow rate was decreased (P<.001) by 39% in the treated eyes compared with baseline values; and uveoscleral outflow was increased (P<.005) by 56% in the treated eye. Peak pulse volume was unchanged.

Conclusion.  —Oxymetazoline reduces intraocular pressure by decreasing aqueous humor flow rates and increasing uveoscleral outflow. Oxymetazoline may have clinical potential as an ocular hypotensive drug.

Add or change institution